# A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

> **NCT07038447** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Kite, A Gilead Company** · enrollment: 52 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Lupus Nephritis
- Systemic Sclerosis
- Idiopathic Inflammatory Myopathy

## Interventions

- **BIOLOGICAL:** KITE-363
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07038447
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-07-02
- **Primary completion:** 2029-07
- **Final completion:** 2029-07
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07038447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07038447, "A Study of KITE-363 in Participants With Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07038447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*